Home » Stocks » RVNC

Revance Therapeutics, Inc. (RVNC)

Stock Price: $24.14 USD -0.65 (-2.62%)
Updated November 30, 4:00 PM EST - Market closed
After-hours: $24.14 0.00 (-0.01%) Nov 30, 5:13 PM

Stock Price Chart

Key Info

Market Cap 1.61B
Revenue (ttm) 4.28M
Net Income (ttm) -249.11M
Shares Out 66.55M
EPS (ttm) -4.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $24.14
Previous Close $24.79
Change ($) -0.65
Change (%) -2.62%
Day's Open 24.54
Day's Range 23.50 - 24.80
Day's Volume 699,421
52-Week Range 12.46 - 34.30

More Stats

Market Cap 1.61B
Enterprise Value 1.37B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 66.55M
Float n/a
EPS (basic) -4.61
EPS (diluted) -4.65
FCF / Share -2.51
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.15M
Short Ratio 7.03
Short % of Float n/a
Beta 1.61
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 375.26
PB Ratio 4.37
Revenue 4.28M
Operating Income -241.36M
Net Income -249.11M
Free Cash Flow -151.87M
Net Cash 232.21M
Net Cash / Share 3.49
Gross Margin 9.65%
Operating Margin -5,638.01%
Profit Margin -5,818.90%
FCF Margin -3,547.61%
ROA -30.35%
ROE -95.05%
ROIC -78.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 10
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(50.62% upside)
Current: $24.14
Target: 36.36
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-88.92%1323.28%-12.67%0%-21.67%-37.93%-13.95%28.73%-
Gross Profit0.413.730.260.300.300.380.620.720.55
Operating Income-164-143-120-88.22-72.32-52.05-38.23-43.19-27.74
Net Income-159-143-121-89.27-73.48-62.92-52.45-58.26-44.86
Shares Outstanding43.4636.1730.1028.1124.3419.390.220.200.20
Earnings Per Share-3.67-3.94-4.01-3.18-3.02-3.241.05-290.48-226.06
Operating Cash Flow-106-104-95.34-59.83-55.67-55.07-47.76-38.91-28.41
Capital Expenditures-3.23-5.45-2.53-1.67-3.33-6.98-6.48-0.32-0.15
Free Cash Flow-109-110-97.87-61.50-59.00-62.05-54.24-39.23-28.56
Cash & Equivalents2911772831862521713.994.1629.70
Total Debt29.34-1.875.358.483.5425.4910668.99
Net Cash / Debt262177282181244168-21.50-102-39.29
Book Value225146269177253176-158-217-155
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Revance Therapeutics, Inc.
Country United States
Employees 193
CEO Mark J. Foley

Stock Information

Ticker Symbol RVNC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RVNC
IPO Date February 6, 2014


Revance Therapeutics, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.